Multi-panel drugs detection in human serum for personalized therapy.

This work focuses on P450 biosensors based on multiwalled carbon nanotubes (MWCNT) and different cytochrome isoforms: 3A4, 2B4, 2C9. The proposed biosensors exhibit enhanced sensitivities and decreased detection limits thanks to carbon nanotubes. The MWCNT structuring improves the sensitivity from 5.1 to 20.5 nA/mM mm(2) in case of CYP2B4-mediated Benzphetamine detection, from 0.26 to 0.63 nA/μM mm(2) in case of CYP3A4-mediated Cyclophosphamide detection, and from 0.11 to 0.25 nA/μM mm(2) in case of CYP2C9-mediated Naproxen detection. By using MWCNT, the limit of detection was enhanced from 59 to 12 μM in case of Cyclophosphamide and from to 187 to 82 μM in case of Naproxen. This makes possible the drug detection in human serum within the pharmacological range. In the paper, a new mathematical model is also proposed to succeed in discriminating different drug contributions in a mixture containing both Cyclophosphamide and Dextromethorphan or combining Naproxen and Flurbiprofen. Data analysis shows variations in reduction peaks that are dependent on the drug ratio, and that are consistent with competitive kinetics of substrates. This new approach enables multiple drug detection and opens the way to possible applications in personalized therapy.

[1]  E. Iwuoha,et al.  Amperometric responses of CYP2D6 drug metabolism nanobiosensor for sertraline: a selective serotonin reuptake inhibitor. , 2007, IET nanobiotechnology.

[2]  J. Leon,et al.  The AmpliChip™ CYP450 Genotyping Test , 2012, Molecular Diagnosis & Therapy.

[3]  Sandro Carrara,et al.  Improved nanocomposite materials for biosensor applications investigated by electrochemical impedance spectroscopy , 2005 .

[4]  F. Young.  Biochemistry , 1955, The Indian Medical Gazette.

[5]  J. Miners,et al.  Electrochemical characterisation of the human cytochrome P450 CYP2C9. , 2005, Biochemical pharmacology.

[6]  Jiunn H Lin,et al.  Pharmacokinetic and pharmacodynamic variability: a daunting challenge in drug therapy. , 2007, Current drug metabolism.

[7]  Sandro Carrara,et al.  Direct electron transfer between cytochrome P450scc and gold nanoparticles on screen-printed rhodium-graphite electrodes. , 2005, Biosensors & bioelectronics.

[8]  A. Rettie,et al.  Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. , 1998, Biochemistry.

[9]  Y. Ivanov,et al.  AFM study of membrane proteins, cytochrome P450 2B4, and NADPH-cytochrome P450 reductase and their complex formation. , 1999, Archives of Biochemistry and Biophysics.

[10]  Eric Boerwinkle,et al.  Personalized medicine for high blood pressure. , 2007, Hypertension.

[11]  Allen J. Bard,et al.  Electrochemical Methods: Fundamentals and Applications , 1980 .

[12]  Richard G. Hamermesh,et al.  Realizing the promise of personalized medicine. , 2007, Harvard business review.

[13]  D. Alberts,et al.  Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial. , 1987, Cancer research.

[14]  F. Juma,et al.  Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration. , 1979, British journal of clinical pharmacology.

[15]  Lei Peng,et al.  Electrochemistry of Cytochrome P450 2B6 on Electrodes Modified with Zirconium Dioxide Nanoparticles and Platin Components , 2008 .

[16]  J. Winter.  Drug Interactions in Infectious Diseases , 2013 .

[17]  Timothy S Tracy,et al.  Atypical enzyme kinetics: their effect on in vitro-in vivo pharmacokinetic predictions and drug interactions. , 2003, Current drug metabolism.

[18]  Lin He,et al.  Electrochemistry of cytochrome P450 enzyme on nanoparticle-containing membrane-coated electrode and its applications for drug sensing. , 2008, Analytical biochemistry.

[19]  U. Fuhr,et al.  Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping , 2007, European Journal of Clinical Pharmacology.

[20]  M. Eichelbaum,et al.  Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil , 2004, European Journal of Clinical Pharmacology.

[21]  Eric F. Johnson,et al.  The Structure of Human Microsomal Cytochrome P450 3A4 Determined by X-ray Crystallography to 2.05-Å Resolution* , 2004, Journal of Biological Chemistry.

[22]  M. Huestis,et al.  Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. , 2003, Clinical chemistry.

[23]  P. Corey,et al.  Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .

[24]  T. Tracy,et al.  Identification of Binding Sites of Non-I-Helix Water Molecules in Mammalian Cytochromes P450 , 2006, Drug Metabolism and Disposition.

[25]  James F Rusling,et al.  An amperometric biosensor with human CYP3A4 as a novel drug screening tool. , 2003, Biochemical pharmacology.

[26]  J. Hammersley,et al.  Monte Carlo Methods , 1965 .

[27]  Kinetics of membrane-bound enzymes: Validity of quasi-steady-state approximation for a Michaelis-Menten-type reaction , 1992 .

[28]  G. P. Kuznetsova,et al.  Electrochemical properties of cytochroms P450 using nanostructured electrodes: direct electron transfer and electro catalysis. , 2007, Journal of inorganic biochemistry.

[29]  Sandro Carrara,et al.  Screen-printed electrodes based on carbon nanotubes and cytochrome P450scc for highly sensitive cholesterol biosensors. , 2008, Biosensors & bioelectronics.

[30]  S. Piscitelli,et al.  Drug interactions in infectious diseases , 2000 .